Literature DB >> 33432491

Spectrum of liver lesions hyperintense on hepatobiliary phase: an approach by clinical setting.

Federica Vernuccio1,2,3,4, Domenico Salvatore Gagliano5, Roberto Cannella6,5, Ahmed Ba-Ssalamah7, An Tang8,9,10, Giuseppe Brancatelli5.   

Abstract

Hepatobiliary MRI contrast agents are increasingly being used for liver imaging. In clinical practice, most focal liver lesions do not uptake hepatobiliary contrast agents. Less commonly, hepatic lesions may show variable signal characteristics on hepatobiliary phase. This pictorial essay reviews a broad spectrum of benign and malignant focal hepatic observations that may show hyperintensity on hepatobiliary phase in various clinical settings. In non-cirrhotic patients, focal hepatic observations that show hyperintensity in the hepatobiliary phase are usually benign and typically include focal nodular hyperplasia. In patients with primary or secondary vascular disorders, focal nodular hyperplasia-like lesions arise as a local hyperplastic response to vascular alterations and tend to be iso- or hyperintense in the hepatobiliary phase. In oncologic patients, metastases and cholangiocarcinoma are hypointense lesions in the hepatobiliary phase; however, occasionally they may show a diffuse, central and inhomogeneous hepatobiliary paradoxical uptake with peripheral rim hypointensity. Post-chemotherapy focal nodular hyperplasia-like lesions may be tricky, and their typical hyperintense rim in the hepatobiliary phase is very helpful for the differential diagnosis with metastases. In cirrhotic patients, hepatocellular carcinoma may occasionally appear hyperintense on hepatobiliary phase.

Entities:  

Keywords:  Gadobenate dimeglumine; Gadoxetate disodium; Hepatocellular carcinoma; Liver neoplasms; Magnetic resonance imaging

Year:  2021        PMID: 33432491     DOI: 10.1186/s13244-020-00928-w

Source DB:  PubMed          Journal:  Insights Imaging        ISSN: 1869-4101


  78 in total

1.  Safety, tolerance, biodistribution, and MR imaging enhancement of the liver with gadobenate dimeglumine: results of clinical pharmacologic and pilot imaging studies in nonpatient and patient volunteers.

Authors:  A Spinazzi; V Lorusso; G Pirovano; M Kirchin
Journal:  Acad Radiol       Date:  1999-05       Impact factor: 3.173

2.  Liver vessel enhancement by Gd-BOPTA and Gd-EOB-DTPA: a comparison in healthy volunteers.

Authors:  T B Brismar; N Dahlstrom; N Edsborg; A Persson; O Smedby; N Albiin
Journal:  Acta Radiol       Date:  2009-09       Impact factor: 1.990

3.  Quantifying differences in hepatic uptake of the liver specific contrast agents Gd-EOB-DTPA and Gd-BOPTA: a pilot study.

Authors:  O Dahlqvist Leinhard; N Dahlström; J Kihlberg; P Sandström; T B Brismar; O Smedby; P Lundberg
Journal:  Eur Radiol       Date:  2011-10-09       Impact factor: 5.315

Review 4.  Benign Hepatocellular Nodules: Hepatobiliary Phase of Gadoxetic Acid-enhanced MR Imaging Based on Molecular Background.

Authors:  Norihide Yoneda; Osamu Matsui; Azusa Kitao; Kazuto Kozaka; Satoshi Kobayashi; Motoko Sasaki; Kotaro Yoshida; Dai Inoue; Tetsuya Minami; Toshifumi Gabata
Journal:  Radiographics       Date:  2016-10-14       Impact factor: 5.333

Review 5.  Primovist, Eovist: what to expect?

Authors:  Bernard E Van Beers; Catherine M Pastor; Hero K Hussain
Journal:  J Hepatol       Date:  2012-04-12       Impact factor: 25.083

6.  Hepatocellular MR contrast agents: enhancement characteristics of liver parenchyma and portal vein after administration of gadoxetic acid in comparison to gadobenate dimeglumine.

Authors:  Sebastian Feuerlein; Rajan T Gupta; Daniel T Boll; Elmar M Merkle
Journal:  Eur J Radiol       Date:  2011-06-29       Impact factor: 3.528

7.  Liver lesions discovered incidentally on ultrasound: evaluation of reader ability to characterize lesions on MRI without intravenous contrast.

Authors:  Neil Hansen; William Weadock; Ajaykumar Morani; Ruth Carlos
Journal:  Acad Radiol       Date:  2012-09       Impact factor: 3.173

Review 8.  The diagnostic value of Gd-EOB-DTPA-MRI for the diagnosis of focal nodular hyperplasia: a systematic review and meta-analysis.

Authors:  Chong Hyun Suh; Kyung Won Kim; Gene Young Kim; Yong Moon Shin; Pyo Nyun Kim; Seong Ho Park
Journal:  Eur Radiol       Date:  2014-12-24       Impact factor: 5.315

Review 9.  Focal Nodular Hyperplasia and Hepatocellular Adenoma: Accuracy of Gadoxetic Acid-enhanced MR Imaging--A Systematic Review.

Authors:  Matthew D F McInnes; Rebecca M Hibbert; João R Inácio; Nicola Schieda
Journal:  Radiology       Date:  2015-05-26       Impact factor: 11.105

10.  Focal hepatic lesions in Gd-EOB-DTPA enhanced MRI: the atlas.

Authors:  José Traila Campos; Claude B Sirlin; Jin-Young Choi
Journal:  Insights Imaging       Date:  2012-06-15
View more
  3 in total

1.  LI-RADS ancillary features favoring benignity: is there a role in LR-5 observations?

Authors:  Roberto Cannella; Federica Vernuccio; Michela Antonucci; Domenico Salvatore Gagliano; Francesco Matteini; Massimo Midiri; Giuseppe Brancatelli
Journal:  Eur Radiol       Date:  2021-09-20       Impact factor: 7.034

2.  Benign Hepatic Nodules in Patients With Primary Extrahepatic Portal Vein Obstruction: Clinical and Magnetic Resonance Imaging Features.

Authors:  Kapil Semalti; Ragini Kilambi; Sujoy Pal; Deep N Srivastava; Peush Sahni; Kumble S Madhusudhan
Journal:  J Clin Exp Hepatol       Date:  2022-04-20

3.  Focal nodular hyperplasia after oxaliplatin-based chemotherapy: A diagnostic challenge.

Authors:  Lorenzo Vassallo; Mirella Fasciano; Mirella Fortunato; Giulio Fraternali Orcioni; Tiziana Vavala'; Daniele Regge
Journal:  Radiol Case Rep       Date:  2022-04-05
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.